Under construction – not a live service
Sign in
Taking people in PortugalPhase 2

Tests ABBV-142 in adults with idiopathic pulmonary fibrosis

Tests ABBV-142 or a placebo in adults with scarring lung disease.

Key facts

Who runs it
AbbVie
Where
Braga, Faro, Loures, Porto, and Senhora Da Hora, PortugalSee the 5 sitesAlso in 20 other countries, 87 sites
Registry title
Study of ABBV-142 to Assess Adverse Events and Change in Disease Activity in Adult Participants With Idiopathic Pulmonary Fibrosis
Status
Recruiting
Phase
Phase 2
People taking part
165 people, planned
Started
23 Jan 2026
Expected to end
Sept 2029
Type of study
Interventional, 2 groupsOne group gets a placebo (a dummy treatment), for comparison.
Treatments tested
  • ABBV-142
  • Placebo for ABBV-142
Record updated
3 September 2026

Who can take part

AI summary

From the trial's eligibility criteria. Machine-read from the registry text on this page, so it can be wrong. The registry text below and the trial team decide who can take part.

The trial is looking for adults with idiopathic pulmonary fibrosis, a lung disease that scars the lungs. It tests the study drug ABBV-142 against a placebo.

Age
40 years or older
Sex
All sexes can join
Disease stage
Idiopathic pulmonary fibrosis diagnosed within 7 years before screening. The investigator confirms it, supported by a chest scan (HRCT) taken within 12 months of screening showing usual or probable usual interstitial pneumonia (UIP).

Main reasons for not taking part

  • A stroke in the 6 months before screening
  • Other lung problems that the investigator considers clinically significant
  • Any cancer in the 5 years before screening, except successfully treated nonmelanoma skin cancer or localized carcinoma in situ of the cervix

The registry criteria, word for word

Show all 4 criteriaShow less

Who can take part

  • Diagnosis of Idiopathic Pulmonary Fibrosis (IPF) within 7 years prior to screening, confirmed by the investigator at screening that is supported by centrally read chest high-resolution computed tomography (HRCT) obtained within 12 months of the screening visit and verification of usual interstitial pneumonia(UIP) or probable UIP

Who cannot take part

  • History of stroke within 6 months prior to screening
  • History of any malignancy up to 5 years prior screening visit, except for successfully treated nonmelanoma skin cancer or localized carcinoma in situ of the cervix
  • In the opinion of the investigator, other clinically significant pulmonary abnormalities

Where in Portugal

Also in 20 other countries, 87 sites

  • CCAB Centro Clinico Academico Braga AssociacaoBraga, PortugalTaking people
  • Unidade Local de Saude do Algarve E.P.E.Faro, PortugalTaking people
  • Unidade Local De Saude De Loures-Odivelas EPELoures, PortugalTaking people
  • Unidade Local de Saude de Sao Joao E.P.E.Porto, PortugalTaking people
  • Unidade Local De Saude De Matosinhos E.P.E.Senhora Da Hora, PortugalTaking people

About the trial

What the trial wants to find out

Idiopathic Pulmonary Fibrosis (IPF) is a rare, long-lasting lung disease that causes scarring of lung tissue, shortness of breath, and loss of lung function. IPF leads to significant loss of quality of life and shortened lifespan. This study is a platform study evaluating different types of treatments in patients with IPF. A platform study is a type of study that uses a single master protocol to evaluate different study treatments allowing for new study treatments or substudies to be added or closed over time. The main goals of the study are to evaluate the safety, tolerability (the degree to which the adverse symptoms can be handled by the patients during the study) and efficacy (how well study treatment works) of the study treatments, including ABBV-142 in Substudy 1 (SS1).

Read full original descriptionShow less

ABBV-142 is an investigational drug being developed for the treatment of IPF. In SS1, participants will be randomly assigned to one of the 2 groups to receive either ABBV-142 or a matching placebo. This study is "double-blind", meaning that neither the participants nor the study doctors know who is given which study treatment. Approximately 165 adult participants with IPF will be enrolled in approximately 125 sites across the world.

Participants will receive ABBV-142 or matching placebo for 52 weeks during the double-blind treatment period. Eligible participants may receive ABBV-142 for 52 weeks in open-label treatment period. All participants will be followed for 120 days.

There may be higher treatment burden for participants in this trial compared to their standard of care. Participants will attend regular visits during the study at a hospital or clinic. The effect of the treatment will be checked by medical assessments, blood tests, checking for side effects and completing questionnaires.

The 2 groups in the trial

  • Substudy 1: ABBV-142Treatment being tested

    Participants will receive ABBV-142 for 52 week during double-blind treatment period. Eligible participants may receive ABBV-142 for 52 weeks during open-label treatment period.

    Treatment: ABBV-142

  • Substudy 1: Placebo for ABBV-142Placebo, for comparison

    Participants will receive placebo for ABBV-142 for 52 week during double-blind treatment period. Eligible participants may receive ABBV-142 for 52 weeks during open-label treatment period.

    Treatment: ABBV-142 and Placebo for ABBV-142

Questions to ask the study team

  1. How often do I need to come in, and for how long each time?
  2. Are travel costs paid?
  3. Can I keep my own doctor?
  4. What happens if I want to stop?

Contact the study team: see the registry record → Contacts and Locations

Print a page for my doctor

Data and sources

Registry record
Listed on ClinicalTrials.gov and on the EU's official list of trials (CTIS).
Official title
A Phase 2a Multicenter Platform Study of Investigational Products for the Treatment of Adult Subjects With Idiopathic Pulmonary Fibrosis
Plain-language title
Tests ABBV-142 in adults with idiopathic pulmonary fibrosisGenerated from the registry record. The registry title is the official one.
AI summary
From the trial's eligibility criteria. Read by machine on 12 November 2026.
Record updated
3 September 2026